Regeneron (REGN) news
Recent news
Alvotech: Pact covers two of its drug candidates in US, Asia
Alvotech has reached a licensing and settlement agreement with Regeneron and Bayer, resolving all remaining patent disputes related to its biosimilar to Eylea® (aflibercept) in markets outside the United States. The agreement grants Alvotech the right to manufacture and supply its aflibercept…
AInvest Wire · Aug 21, 2026InfiniImmune: $75 mln Series A financing co-led by Regeneron Ventures and Playground Global
AInvest Wire · Aug 11, 2026Regeneron Pharmaceuticals Inc: Citigroup raises target price to $740 from $700
AInvest Wire · Aug 3, 2026Biocon: launch of biosimilar to Regeneron’s Eylea
AInvest Wire · Aug 3, 2026Biocon: U.S. commercial launch of Yesafili
Biocon Biologics has secured a U.S. commercial launch for Yesafili (aflibercept-jbvf), an interchangeable biosimilar to Regeneron Pharmaceuticals’ Eylea (aflibercept), following a settlement agreement with Regeneron. The agreement resolves patent litigation and allows Biocon to launch Yesafili in…
AInvest Wire · Aug 3, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.